BioSyent Inc. (CVE:RX - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$11.35 and traded as high as C$11.43. BioSyent shares last traded at C$11.43, with a volume of 100 shares changing hands.
BioSyent Price Performance
The stock has a market capitalization of C$129.46 million, a P/E ratio of 18.62 and a beta of 0.93. The business has a fifty day simple moving average of C$11.36 and a 200-day simple moving average of C$10.80. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13.
Insiders Place Their Bets
In other BioSyent news, Senior Officer Robert Joseph March sold 4,775 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total transaction of C$55,628.75. Also, insider FAX Capital Corp. sold 112,400 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total value of C$1,267,557.28. In the last three months, insiders have sold 349,144 shares of company stock worth $3,903,370. Corporate insiders own 33.65% of the company's stock.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Articles
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
